News and Comments

Cytokinetics Heart Failure Drug Worked

  Tuesday, October 27, 2015

POSITIVE TOP-LINE RESULTS FROM A PHASE 2 TRIAL OF OMECAMTIV MECARBIL IN PATIENTS WITH CHRONIC HEART FAILURE More...

CYTOKINETICS: THE MOMENT OF HALF THE TRUTH

  Friday, April 25, 2014

Bad news has come from Cytokinetics' (CYTK) top-line results of BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). Bottom line, BENEFIT-ALS trial did not achieve its primary efficacy endpoint, the mean change from baseline in the ALS Functional Rating Scale in its revised form (ALSFRS-R) on tirasemtiv versus placebo (-2.98 points in the tirasemtiv group versus -2.40 points in the placebo group, p = 0.11). Another ambitious attempt to decrease some of ALS burden on the sufferers has disappointed.  
 More...

UNREASONABLE CAUSE FOR SELLING CYTK

  Monday, July 08, 2013

The BENEFIT-ALS TRIALS: Cytokinetics (CYTK) announced an update on the conduct of BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS).  The BENEFIT-ALS is a Phase 2b, multinational, double-blind, randomized, placebo-controlled clinical trial designed to evaluate the safety, tolerability and potential efficacy of tirasemtiv, a fast skeletal muscle troponin activator, in patients with amyotrophic lateral sclerosis (ALS). More...

CYTOKINETICS’ NEW PLAN WITH AMGEN INCREASES THE DOSE OF OPTIMISM TOWARDS THE H.F. DRUG.

  Sunday, February 06, 2011

In the news, Cytokinetics (CYTK) announced that, in the first half of 2011, the company and Amgen (AMGN) have agreed to initiate a Phase IIb clinical trial of an intravenous formulation of omecamtiv mecarbil for patients with left ventricular systolic dysfunction hospitalized for acute heart failure. Amgen will conduct the trial in collaboration with Cytokinetics.  More...

CYTOKINETICS (CYTK) And The Moment Of Truth

  Sunday, December 19, 2010

Rushing to wrong interpretations of the news and the triggering of computer programmed-selling of biotech stocks on good news devastate serious biotech sector shareholders. Also, routinely instigating sell offs of development-stage firms at each and every quarterly financial announcement of negative income, knowing in fact that these firms have yet to put products on the market, boxes these stocks. Now, we are witnessing another pattern of computer programmed selling, i.e. activation following announcements of clinical trial results, regardless of whether these results are positive or negative.  More...


Recent Postings


Archive


Tags

Herceptin ImmunoGen (IMGN) GUARDIAN HEALTH ABBVIE (ABBV) VANDA (VNDA) Human Genome Sciences (HGSI) Sanofi-Aventis (SAN) SUNESIS PHARMACEUTICALS (SNSS) CompuGen (CGEN) Dynavax (DVAX) Sangamo (SGMO) Auspex (ASPX) Genentech Seattle Genetics (SGEN) Anacor (ANAC) Pluristem (PSTI) Agenus (AGEN) Roche (RHHBY) Multiple Myeloma Prosensa (RNA) Anadys (ANDS) Aimmune Therapeutics (AIMT) Ionis (IONS) Vitae Pharmaceuticals (VTAE) Sarepta (SRPT) Telaprevir Ridaforolimus Theravance Bio Pharma (TBPH) Gilead (GILD) KERYX (KERX) Regeneron (REGN) Human Longevity (HLI) Jazz Pharmaceuticals (JAZZ) SERES THERAPEUTICS (MCRB) Ziofpharm (ZIOP) AERIE PHARMACEUTICALS Velcade (bortezomib) SYNTA (SNTA) GlaxoSmithKline (GSK) Revlimid (lenolidamide) C4 Therapeutics Micromet (MITI) Roche (ROCHE) Array Pharmaceuticals (ARRY) Dendreon (DNDN) KITE (KITE) Sequenom (SQNM) Intercept (ICPT) Sanofi (SNA) Zerenex BIOMARIN (BMRN) Bristol-Myers Squibb (BMY) Idenix (IDIX) Benlysta (belimumab) Amgen (AMGN) Xoma (XOMA) NEKTAR (NKTR)) Intermune (ITMN) REGULUS (RGLS) Incyte (INCY) OSI (OSIP) Merck (MRK) Valeant Pharmaceuticals International (VRX) ACADIA (ACAD) JUNO (JUNO) Sanofi (SNY) Inovio (INO) Alnylam (ALNY) ISIS (ISIS) Cytokinetics (CYTK) ARCA (ABIO) HALOZYME (HALO) galapagos (GLPG) Vertex (VRTX) Biocryst (BCRX) Onyx (ONXX) Illumina (ILMN) NANTKWEST (NK) IDERA (IDRA) Abbott Laboratories (ABT) Intrexon (XON) Tysabri Trastuzumab-DM1 ADVENTRIX (ANX) Exelixis (EXEL) Mirati Therapeutics (MRTX) Galena (GALE) Elan (ELN) Prolor Biotech (PBTH) ZALTRAP™ Endometrial Cancer Biogen Idec (BIIB) TOKAI (TKAOI) Alder Biopharmaceuticals (ALDR) Theravance (THRX) Rapamune Agenus (AGEN Ariad (ARIA)